{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=30", "query": { "intervention": "Branch II", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 4754, "total_pages": 476, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Branch+II&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T07:58:05.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00148317", "title": "Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "cyclophoshamide", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2005-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-07-18", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148317" }, { "nct_id": "NCT03150693", "title": "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Allopurinol", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pegylated L-Asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 303, "start_date": "2017-09-20", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03150693" }, { "nct_id": "NCT00006604", "title": "Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ATV", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "91 Days", "maximum_age": "21 Years", "sex": "ALL", "summary": "91 Days to 21 Years" }, "enrollment_count": 195, "start_date": "2000-11", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2021-11-05", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006604" }, { "nct_id": "NCT02489448", "title": "Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2015-11", "completion_date": "2021-08-02", "has_results": true, "last_update_posted_date": "2022-10-26", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489448" }, { "nct_id": "NCT00742417", "title": "Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Albutein 5%", "type": "BIOLOGICAL" }, { "name": "Control", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Instituto Grifols, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 42, "start_date": "2007-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-06-14", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Whiting, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Whiting", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00742417" }, { "nct_id": "NCT01281176", "title": "High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 20, "start_date": "2011-02-09", "completion_date": "2027-04-17", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281176" }, { "nct_id": "NCT00841204", "title": "Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precancerous Condition" ], "interventions": [ { "name": "sulindac", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2009-02", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 2, "location_summary": "Tucson, Arizona • Stanford, California", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00841204" }, { "nct_id": "NCT04527549", "title": "Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Dabrafenib mesylate", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Trametinib dimethyl sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2021-06-01", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 199, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04527549" }, { "nct_id": "NCT02439255", "title": "Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy Subject", "Tobacco Use Disorder" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Phytochemical", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Screening Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 148, "start_date": "2015-12-04", "completion_date": "2022-04-30", "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439255" }, { "nct_id": "NCT04830735", "title": "Dasatinib for the Treatment of Moderate and Severe COVID-19", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Symptomatic COVID-19 Infection Laboratory-Confirmed" ], "interventions": [ { "name": "Dasatinib Anhydrous", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-08-05", "completion_date": "2024-12-15", "has_results": false, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-10-20T07:58:05.496Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04830735" } ] }